NICE recommends use of Selincro for Alcohol Dedendence - Lundbeck
The National Institute for Health and Care Excellence (NICE) has recommended Selincro (nalmefene) from Lundbeck as an option to treat Alcohol Dependence in draft guidance. The recommendation covers the use of Selincro for cutting alcohol consumption in those without physical withdrawal symptoms and who do not require immediate detoxification. This is the first time, patients will have access to a pill to reduce alcohol intake rather than stop it altogether, which some experts believe is a more realistic treatment aim. Selincro was approved in Europe in March 2013 after demonstrating in trials a 40 per cent reduction on total alcohol consumption within the first month. This increased to 60 per cent following six months of treatment with Selincro. Lundbeck has already launched the drug in the UK.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins